Nonsteroidal Anti-Inflammatory Drugs and Melanoma Risk
Author Information
Author(s): Joanne M. Jeter, Joseph D. Bonner, Timothy M. Johnson, Stephen B. Gruber
Primary Institution: University of Michigan Cancer Center
Hypothesis
Do nonsteroidal anti-inflammatory drugs (NSAIDs) convey a chemoprotective effect against melanoma?
Conclusion
The study found no significant association between analgesic use and melanoma risk after accounting for potential confounders.
Supporting Evidence
- Regular use of aspirin was reported by 10.9% of controls.
- Approximately 14% of control subjects reported regular use of nonaspirin NSAIDs.
- Among melanoma subjects, 104 had in situ melanoma, 223 had a first melanoma, and 63 had multiple primary melanomas.
Takeaway
The study looked at whether pain relievers like aspirin and other NSAIDs help prevent skin cancer called melanoma, but it found that they don't really make a difference.
Methodology
A case-control study with structured interviews assessing melanoma risk factors among subjects with melanoma and controls.
Potential Biases
Selection bias may be present in the control group as not all spouses of melanoma subjects participated.
Limitations
The study could not validate medication use with prescription records and lacked a validated measure for sun exposure.
Participant Demographics
327 melanoma cases and 119 melanoma-free controls, with a median age of 53 for cases and 56 for controls.
Statistical Information
Confidence Interval
0.31–1.11 for nonaspirin NSAIDs; 0.43–1.69 for aspirin.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website